Loading
Claritev Corp Stock: price and insider trades · United States
1 insider bought €214k of shares over the last 90 days, the latest filed 31 Aug 2026.
Claritev Corp: what insiders have been doing
This page follows insider dealings at Claritev Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in McLean, United States. The group dates from 1980. Its latest reported headcount is 2,800 employees (2025). In the past year (18 October 2025 to 18 October 2026), 50 filings came from 22 insiders.
Open-market activity splits into 12 purchases totalling €1.6M and 6 sales totalling €34.1M; 6 insiders sit on the buying side and 4 insiders on the selling side. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 4 senior executives, 1 finance chief and 1 chief executive. Biggest ticket of the year: €33.2M, sold by H&F Corporate Investors VIII, Ltd. and made public on 14 November 2025.
With 50 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2021, counts 29 purchases against 8 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 965.4 m USD and net income of -284.3 m USD.
The data flag 9 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 31 August 2026, which is 48 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
191
Thresholds
n/a
Buy Volume
€5M
29 ops. · all time
Sell Volume
€43M
8 ops. · all time
Who traded when
BuySaleTravis Dalton7 buys
Douglas Michael Garis4 buys2 sales
Kim Michael4 buys
O'Neil Tara3 buys
Hogge Jerome2 buys
Tiffani Misencik2 sales
+3 other insiders
Since the insiders bought
- -44.0%Entry US$39.35 · Close 16 Oct 2026 US$22.05
- -31.2%Entry US$32.03 · Close 16 Oct 2026 US$22.05
- +80.9%Entry US$16.92 · Close at T+90 US$30.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Claritev Corp Buy (bullish), based on 5 analysts. Average price target: US$46.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,559 of 24,148 companies
30.1
score / 100
Value28
Quality32
FCF yld-3.2%
Earn yld-75%
EV/EBITDA10.7x
ROE·
Gross mgn67%
Net mgn-29%
Debt/EBITDA9.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.47
Analyst consensus
5 analystsBuy
US$30.00Target US$46.00(+105%)US$73.00
Income statement
RevenueUS$965.4M
Gross profitUS$649M67% margin
EBITDAUS$467.4M48% margin
Net income-US$284.3M-28.5% margin
Valuation
PER (forward)3.1x
Beta0.89
Balance sheet & cash
Market capUS$380.8M
Total debtUS$4.6B
Free Cash Flow-US$12.3M
Profitability & ownership
ROA1.2%
% insiders7.3%
% institutions90.2%
Last declaration on 16 October 2026
Declarations191 total
9,994 shares@ US$23.940.063% mcap20.7% of flowClass A common stockSEC:0002041258-26-000006:0
5,812 shares@ US$23.81110.036% mcap12.0% of flowClass A common stockSEC:0002041258-26-000006:1
5,812 shares@ US$23.940.038% mcap28.8% of flowCommonSEC144:0001950047-26-010268
7,877 shares@ US$30.50210.056% mcap18.0% of flowClass A common stockSEC:0002032799-26-000008:0
1,148 shares@ US$31.19340.0084% mcap2.7% of flowClass A common stockSEC:0002032799-26-000008:1
9,025 shares@ US$30.810.065% mcap100.0% of flowCommonSEC144:0001950047-26-009699
2,880 shares0Class A common stockSEC:0002153513-26-000007:0
4,500 shares@ US$38.80520.040% mcap11.3% of flowClass A common stockSEC:0001628280-26-059472:0
Canonical exit: 25 Nov 2026 (T+90)
1,950 shares@ US$38.48230.017% mcap4.9% of flowClass A common stockSEC:0001628280-26-059472:1
Canonical exit: 26 Nov 2026 (T+90)
8,850 shares@ US$40.0670.082% mcap44.4% of flowClass A common stockSEC:0002041258-26-000004:0
8,850 shares@ US$40.06690.082% mcap100.0% of flowCommonSEC144:0001950047-26-008188
8,431 shares@ US$34.240.067% mcap50.1% of flowClass A common stockSEC:0002033015-26-000006:0
8,431 shares@ US$34.240.067% mcap100.0% of flowCommonSEC144:0001950047-26-007921
11,711 shares@ US$26.130.071% mcap22.8% of flowClass A common stockSEC:0002032799-26-000006:0
3,622 shares@ US$26.130.022% mcap16.5% of flowClass A common stockSEC:0002033015-26-000004:0
3,649 sharesClass A common stockSEC:0001636355-26-000009:0
875 sharesClass A common stockSEC:0001962112-26-000007:0
Canonical exit: 7 Sept 2026 (T+90)
8,977 shares0Class A common stockSEC:0001628280-26-029356:0
8,977 shares0Class A common stockSEC:0001236982-26-000003:0
8,977 shares0Class A common stockSEC:0001338905-26-000002:0
8,977 shares0Class A common stockSEC:0001359335-26-000002:0
8,977 shares0Class A common stockSEC:0001628280-26-029357:0
8,977 shares0Class A common stockSEC:0001982656-26-000002:0
8,977 shares0Class A common stockSEC:0002066692-26-000002:0
2,956 shares0Class A common stockSEC:0001636355-26-000007:0
25 of 191 declarations
About Claritev Corp
Claritev Corp. (NYSE: CTEV) is a U.S.-listed healthcare technology, data, and analytics company in the United States, trading on the NYSE. The company was formerly known as MultiPlan and rebranded to Claritev in 2025 as part of a broader strategic reset aimed at emphasizing transparency, affordability, and data-driven decision-making across the U.S. healthcare system. Claritev traces its roots back to 1980, when it began as a New York-based hospital network, and has since evolved through organic growth and acquisitions into a national healthcare cost-management platform.
Claritev’s business is organized around three core service lines. First are analytics-based services, which use algorithms and multiple data sources to detect claims overcharges, recommend fair reimbursement levels, and help clients manage medical cost inflation. Second are network-based services, where Claritev negotiates provider discounts and builds large PPO-style networks; the company describes itself as operating one of the largest independent PPO networks in the United States. Third are payment and revenue integrity services, which are designed to identify and remove improper or unnecessary charges before or after claims are paid, and to help recover underpaid premium dollars. Together, these capabilities position Claritev at the intersection of claims repricing, provider network management, and healthcare price transparency.
Read moreShow less
From a competitive standpoint, Claritev markets itself as a scaled, tech-enabled intermediary serving payers, employers, patients, providers, and third parties. Its differentiation rests on a proprietary data ecosystem, decades of claims repricing experience, and increasingly on AI-enabled tools that support pricing, payment accuracy, and network optimization. The company states that it serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers, underscoring the breadth of its national footprint.
Key products and solutions include its national and regional provider networks, claims intelligence offerings, price transparency tools, and network design and management services. Claritev’s core market remains the United States, although management has also highlighted selective international adjacency through strategic initiatives, including an investment in Klaim to support payment acceleration solutions across the U.S. and the MENA region.
Recent highlights are constructive. In May 2026, Claritev reported first-quarter results showing revenue and Adjusted EBITDA growth, while slightly raising its full-year 2026 revenue outlook. In February 2026, the board approved a $75 million share repurchase program over five years, signaling confidence in the cash generation profile and capital allocation framework. For investors tracking U.S. healthcare services and data-enabled cost containment, Claritev remains a notable NYSE name with a large addressable market, strong operating leverage potential, and an ongoing strategic transformation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
